Masashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology.

Boards, Advisory Committees, Professional Organizations

  • Board Certified Hematologist, Japanese Society of Hematology (2017 - Present)
  • Board Certified Occupational Physician, , Japanese Medical Association (2018 - Present)

Professional Education

  • Doctor of Medicine, Kyoto University (2009)
  • Doctor of Philosophy, University Of Tokyo (2019)
  • Clinical Fellow, The University of Tokyo Hospital, Hematology (2017)
  • Clinical Traninig, The University of Tokyo, Clinical Oncology (2015)
  • Doctor of Philosophy, The University of Tokyo, Medicine (2015)
  • Doctor of Medicine, Kyoto University (2009)

Stanford Advisors

All Publications

  • Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Matsuda, K., Jo, T., Miyauchi, M., Toyama, K., Nakazaki, K., Matsui, H., Fushimi, K., Yasunaga, H., Kurokawa, M. 2021; 27 (8): 1151-1155


    There has been no comprehensive analysis of the age-specific efficacy of G-CSF to prevent febrile neutropenia (FN). We evaluated factors associated with FN occurrence according to patient age in rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP) treatment.We retrospectively reviewed diffuse large B-cell lymphoma (DLBCL) patients aged ≥50 years, who underwent the first R-CHOP cycle between July 2010 and March 2017, using a Japanese inpatient database. Multivariable logistic regression analysis was performed to identify the factors associated with FN.A total of 16,399 patients with untreated DLBCL were identified. Primary prophylaxis with pegfilgrastim was significantly associated with the lower occurrence of FN (odds ratio: 0.71 [95% confidence interval: 0.51-0.99]). Subgroup analysis according to age was then performed. Although there was no significance, primary prophylaxis with pegfilgrastim tended to have a lower odds ratio for the occurrence of FN in patients aged 50-60 years (0.86 [0.39-1.89]) and 61-70 years (0.64 [0.36-1.13]). In patients aged 71-80 years, primary prophylaxis with pegfilgrastim was significantly associated with reduced FN occurrence (0.46 [0.26-0.80]). Notably, in patients aged >80 years, the use of pegfilgrastim tended to be associated with a rather higher occurrence of FN (1.55 [0.84-2.87]).Preventing effect of G-CSF may be limited in patients aged >80 years.

    View details for DOI 10.1016/j.jiac.2021.03.004

    View details for PubMedID 33745811

  • A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Annals of hematology Sasaki, K., Matsuda, K., Miyauchi, M., Honda, A., Shimura, A., Masamoto, Y., Kurokawa, M. 2021; 100 (5): 1341-1343

    View details for DOI 10.1007/s00277-021-04453-8

    View details for PubMedID 33783549

  • Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. Experimental hematology Honda, A., Koya, J., Yoshimi, A., Miyauchi, M., Taoka, K., Kataoka, K., Arai, S., Kurokawa, M. 2021; 101-102: 42-48.e11


    Primary refractory acute myeloid leukemia (AML) is unresponsive to conventional chemotherapy and has a poor prognosis. Despite the recent identification of novel driver mutations and advances in the understanding of the molecular pathogenesis, little is known about the relationship between genetic abnormalities and chemoresistance in AML. In this study, we subjected 39 samples from patients with primary refractory AML to whole-exome and targeted sequencing analyses to identify somatic mutations contributing to chemoresistance in AML. First, we identified 49 genes that might contribute to chemotherapy resistance through the whole-exome sequencing of samples from 6 patients with primary refractory AML. We then identified a significantly higher frequency of mutations in the gene encoding BCL-6 co-repressor (BCOR) in patients with primary refractory AML through the targeted sequencing of all coding sequence of 49 genes. Notably, the presence of BCOR mutations appeared to have a negative impact on prognosis in our cohort and previous larger studies. Subsequently, to investigate the biological effect of BCOR mutations on sensitivity to anticancer drugs, we established BCOR knockout human leukemic cell lines using the CRISPR/Cas9 system. Here, BCOR knockout cell lines exhibited statistically significant reductions in sensitivity to anticancer drugs, compared with the wild-type controls both in vitro and in vivo in xenograft mouse models. In conclusion, loss-of-function BCOR mutations appear to contribute to chemotherapy resistance and may be a promising therapeutic target in primary refractory AML.

    View details for DOI 10.1016/j.exphem.2021.07.005

    View details for PubMedID 34333045

  • CAMK2G is identified as a novel therapeutic target for myelofibrosis. Blood advances Miyauchi, M., Sasaki, K., Kagoya, Y., Taoka, K., Masamoto, Y., Yamazaki, S., Arai, S., Mizuno, H., Kurokawa, M. 2021


    Although JAK1/2 inhibition is effective into alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here we established iPS cells derived from MF patient samples (MF-iPSCs) harboring JAK2 V617F, CALR type 1, or CALR type 2 mutations. We demonstrated that these cells faithfully recapitulate the drug sensitivity of the disease. These cells were utilized for chemical screening and calcium/calmodulin-dependent protein kinase 2 (CAMK2) was identified as a promising therapeutic target. MF model cells and mice induced by MPL W515L, another type of mutations recurrently detected in MF patients were used to elucidate the therapeutic potential of CAMK2 inhibition. CAMK2 inhibition was effective against JAK2 inhibitor-sensitive and JAK2 inhibitor-resistant cells. Further research revealed CAMK2 gamma subtype was important in MF model cells induced by MPL W515L. We showed that CAMK2G hetero knockout in the primary bone marrow cells expressing MPL W515Ldecreased colony-forming capacity. CAMK2G inhibition with berbamine, a CAMK2G inhibitor, significantly prolonged survival and reduced disease phenotypes such as splenomegaly and leukocytosis in a MF mouse model induced by MPL W515L. We investigated the molecular mechanisms underlying the therapeutic effect of CAMK2G inhibition and found that CAMK2G is activated by MPL signaling in MF model cells and is an effector in the MPL-JAK2 signaling pathway in these cells. These results indicate CAMK2G plays an important role in MF, and CAMK2G inhibition may be a novel therapeutic strategy that overcomes resistance to JAK1/2 inhibition.

    View details for DOI 10.1182/bloodadvances.2020003303

    View details for PubMedID 34521112

  • Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment. Blood Masashi, M., Ito, Y., Nakahara, F., Hino, T., Nakamura, F., Iwasaki, Y., Kawagoshi, T., Koya, J., Yoshimi, A., Arai, S., Kagoya, Y., Kurokawa, M. 2021


    Neutrophils play an essential role in innate immune responses to bacterial and fungal infections and loss of neutrophil function can increase the risk of acquiring lethal infections in clinical settings. Here, we show that engineered neutrophil-primed progenitors derived from human induced pluripotent stem cells (iPSCs) can produce functional neutrophil-like cells at a clinically applicable scale that can act rapidly in vivo against lethal bacterial infections. Using five different mouse models, we systematically demonstrated that these neutrophil-like cells migrate to sites of inflammation and infection and increase survival against bacterial infection. In addition, we found that these human neutrophil-like cells can recruit murine immune cells. This system potentially provides a straight-forward solution for patients with neutrophil deficiency-an off-the-shelf neutrophil transfusion. This platform should facilitate the administration of human neutrophils for a broad spectrum of physiological and pathological conditions.

    View details for DOI 10.1182/blood.2021011576

    View details for PubMedID 34587247

  • Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses. Leukemia & lymphoma Matsuda, K. n., Taisuke, J. n., Miyauchi, M. n., Toyama, K. n., Nakazaki, K. n., Matsui, H. n., Fushimi, K. n., Yasunaga, H. n., Kurokawa, M. n. 2020; 61 (10): 2435–41


    The clinical impact of pegfilgrastim in day-to-day practice remains unclear. This study evaluated the effectiveness of pegfilgrastim compared with daily filgrastim in patients with DLBCL who received the first-cycle of R-CHOP treatment by using a Japanese national inpatient database. Patient characteristics were adjusted by using propensity-score matching and stabilized inverse probability of treatment weighting (IPTW). In 1295 propensity-score-matched pairs, the incidence of febrile neutropenia was significantly lower in the pegfilgrastim group (risk difference 6.1%, 95% CI 4.1%-8.1%) than in the filgrastim group. In the pegfilgrastim group, the length of hospital stay and the total costs were also significantly reduced (percent reduction 34% [95% CI: 31%-37%], percent reduction 12% [95% CI: 9%-15%], respectively). The stabilized IPTW showed comparable results. In day-to-day practice, the simple mode of pegfilgrastim administration may be advantageous.

    View details for DOI 10.1080/10428194.2020.1775207

    View details for PubMedID 32529865

  • Significance of biopsy with ERCP for diagnosis of bile duct invasion of DLBCL. International journal of hematology Ito, Y. n., Miyauchi, M. n., Nakamura, T. n., Takahara, N. n., Nakai, Y. n., Taoka, K. n., Toyama, K. n., Shinozaki-Ushiku, A. n., Koike, K. n., Kurokawa, M. n. 2019


    Obstructive jaundice is an initial symptom in 1-2% of diffuse large B cell lymphoma (DLBCL) cases. The major cause of bile duct obstruction in patients with DLBCL is extrinsic compression by enlarged lymph nodes. In such cases, the existence of bile duct invasion of lymphoma is rarely mentioned or observed pathologically, so the ratio of bile duct invasion to the total cases of obstructive jaundice, and its significance remains unknown. We report two cases of DLBCL presenting as an obstructive jaundice, in which we demonstrated bile duct invasion pathologically by biopsy from the wall of common bile duct with endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic stent placement is a minimally invasive procedure to relieve cholestasis and is effective for diagnosing bile duct invasion. This procedure should thus be performed in all cases of obstructive jaundice caused by lymphoma to evaluate for bile duct invasion. Our cases suggest that ERCP may be useful as a diagnostic procedure for bile duct invasion.

    View details for DOI 10.1007/s12185-019-02661-7

    View details for PubMedID 31093933

  • Arteritis after administration of granulocyte colony-stimulating factor: a case series. International journal of hematology Sasaki, K. n., Miyauchi, M. n., Ogura, M. n., Shimura-Nukina, A. n., Toyama, K. n., Nakazaki, K. n., Watadani, T. n., Abe, O. n., Kurokawa, M. n. 2019


    Granulocyte colony-stimulating factor (G-CSF) is commonly administered to prevent serious complications caused by chemotherapy-induced neutropenia; however, several cases of arteritis following the administration of G-CSF have been reported. Here, we report three cases of patients with non-Hodgkin lymphomas (NHLs) who developed arteritis after the administration of G-CSF, estimate the probability of adverse drug reaction caused by G-CSF with two distinct algorithms, and review the literatures. Both algorithms indicated a causal relationship between G-CSF and arteritis. In a literature review of seven reported cases, including our three patients, the time from the administration of G-CSF to the onset of arteritis ranged from 9 days to 6 months, and five patients were treated with steroids. In one of our three cases, a 62-year-old female with NHL developed arteritis twice in different courses of chemotherapy. Hydrocortisone was administered in the second event, leading to prompt relief of the manifestation and abnormal laboratory data. This finding suggests steroids may be effective for arteritis. In conclusion, although the number of reported cases is limited, there appears to be an association between arteritis and the administration of G-CSF, and steroids are an effective therapeutic option.

    View details for DOI 10.1007/s12185-019-02662-6

    View details for PubMedID 31090035

  • Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Scientific reports Taoka, K. n., Arai, S. n., Kataoka, K. n., Hosoi, M. n., Miyauchi, M. n., Yamazaki, S. n., Honda, A. n., Aixinjueluo, W. n., Kobayashi, T. n., Kumano, K. n., Yoshimi, A. n., Otsu, M. n., Niwa, A. n., Nakahata, T. n., Nakauchi, H. n., Kurokawa, M. n. 2018; 8 (1): 15855


    Chronic myelomonocytic leukemia (CMML) is an entity of myelodysplastic syndrome/myeloproliferative neoplasm. Although CMML can be cured with allogeneic stem cell transplantation, its prognosis is generally very poor due to the limited efficacy of chemotherapy and to the patient's age, which is usually not eligible for transplantation. Comprehensive analysis of CMML pathophysiology and the development of therapeutic agents have been limited partly due to the lack of cell lines in CMML and the limited developments of mouse models. After successfully establishing patient's derived disease-specific induced pluripotent stem cells (iPSCs) derived from a patient with CMML, we utilized these CMML-iPSCs to achieve hematopoietic re-differentiation in vitro, created a humanized CMML mouse model via teratomas, and developed a drug-testing system. The clinical characteristics of CMML were recapitulated following hematopoietic re-differentiation in vitro and a humanized CMML mouse model in vivo. The drug-testing system using CMML-iPSCs identified a MEK inhibitor, a Ras inhibitor, and liposomal clodronate as potential drugs for treating CMML. Clodronate is a drug commonly used as a bisphosphonate for osteoporosis. In this study, the liposomalization of clodronate enhanced its effectiveness in these assays, suggesting that this variation of clodronate may be adopted as a repositioned drug for CMML therapy.

    View details for DOI 10.1038/s41598-018-34193-1

    View details for PubMedID 30367142

    View details for PubMedCentralID PMC6203784

  • ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem cell reports Miyauchi, M. n., Koya, J. n., Arai, S. n., Yamazaki, S. n., Honda, A. n., Kataoka, K. n., Yoshimi, A. n., Taoka, K. n., Kumano, K. n., Kurokawa, M. n. 2018; 10 (3): 1115–30


    Properties of cancer stem cells involved in drug resistance and relapse have significant effects on clinical outcome. Although tyrosine kinase inhibitors (TKIs) have dramatically improved survival of patients with chronic myeloid leukemia (CML), TKIs have not fully cured CML due to TKI-resistant CML stem cells. Moreover, relapse after discontinuation of TKIs has not been predicted in CML patients with the best TKI response. In our study, a model of CML stem cells derived from CML induced pluripotent stem cells identified ADAM8 as an antigen of TKI-resistant CML cells. The inhibition of expression or metalloproteinase activity of ADAM8 restored TKI sensitivity in primary samples. In addition, residual CML cells in patients with optimal TKI response were concentrated in the ADAM8+ population. Our study demonstrates that ADAM8 is a marker of residual CML cells even in patients with optimal TKI response and would be a predictor of relapse and a therapeutic target of TKI-resistant CML cells.

    View details for DOI 10.1016/j.stemcr.2018.01.015

    View details for PubMedID 29429960

    View details for PubMedCentralID PMC5919294

  • Modeling of hematologic malignancies by iPS technology. Experimental hematology Arai, S. n., Miyauchi, M. n., Kurokawa, M. n. 2015; 43 (8): 654–60


    Induced pluripotent stem cells (iPSCs) can be generated from various types of cells with transduction of defined transcription factors. Patient-derived iPSCs are becoming commonly utilized for understanding the molecular pathways involved in disease and for the development of novel targeted therapies. With the use of patient-derived iPSCs differentiated to specific-lineage cells, the potency and toxicity of drug candidates can be evaluated. In the past, patient-derived iPSCs were mainly established from patients of inherited hematologic diseases, followed by the expansion of target to acquired diseases like myeloproliferative neoplasms. Thanks to the rapid development of novel genome editing technologies, we can now utilize genetically modified and unprocessed iPSCs more readily than before. These technologies, which enable us to modulate genetic status or even chromosome structure at the right time, could help the elucidation of pathogenesis of hematologic diseases. If iPSC-derived hematopoietic cells are to be robustly reconstituted in vivo as a consequence of the development of reprogramming and conversion technology, research on leukemic stem cells must be widely promoted. Therefore, iPSC technology has great potential on oncology research using patient samples.

    View details for DOI 10.1016/j.exphem.2015.06.006

    View details for PubMedID 26135030

  • Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental hematology Iizuka, H. n., Kagoya, Y. n., Kataoka, K. n., Yoshimi, A. n., Miyauchi, M. n., Taoka, K. n., Kumano, K. n., Yamamoto, T. n., Hotta, A. n., Arai, S. n., Kurokawa, M. n. 2015; 43 (10): 849–57


    Familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML) is an autosomal dominant disease associated with a germline mutation in the RUNX1 gene and is characterized by thrombocytopenia and an increased risk of developing myeloid malignancies. We generated induced pluripotent stem cells (iPSCs) from dermal fibroblasts of a patient with FPD/AML possessing a nonsense mutation R174X in the RUNX1 gene. Consistent with the clinical characteristics of the disease, FPD iPSC-derived hematopoietic progenitor cells were significantly impaired in undergoing megakaryocytic differentiation and subsequent maturation, as determined by colony-forming cell assay and surface marker analysis. Notably, when we corrected the RUNX1 mutation using transcription activator-like effector nucleases in conjunction with a donor plasmid containing normal RUNX1 cDNA sequences, megakaryopoiesis and subsequent maturation were restored in FPD iPSC-derived hematopoietic cells. These findings clearly indicate that the RUNX1 mutation is robustly associated with thrombocytopenia in patients with FPD/AML, and transcription activator-like effector nuclease-mediated gene correction in iPSCs generated from patient-derived cells could provide a promising clinical application for treatment of the disease.

    View details for DOI 10.1016/j.exphem.2015.05.004

    View details for PubMedID 26021490

  • [Induced pluripotent stem cells from leukemia patients as a platform for dissecting pathogenesis]. [Rinsho ketsueki] The Japanese journal of clinical hematology Kurokawa, M., Miyauchi, M. 2014; 55 (10): 2202-7

    View details for PubMedID 25297788

  • Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation. International journal of hematology Miyauchi, M. n., Yoshimi, A. n., Nannya, Y. n., Takazawa, Y. n., Ichikawa, M. n., Fukayama, M. n., Kurokawa, M. n. 2012; 96 (1): 146–48

    View details for DOI 10.1007/s12185-012-1110-1

    View details for PubMedID 22684925

  • Pituitary lymphoma developing within pituitary adenoma. International journal of hematology Morita, K. n., Nakamura, F. n., Kamikubo, Y. n., Mizuno, N. n., Miyauchi, M. n., Yamamoto, G. n., Nannya, Y. n., Ichikawa, M. n., Kurokawa, M. n. 2012; 95 (6): 721–24


    Lymphoma occurring in the pituitary gland is an exceedingly infrequent event. Here, we describe a case of pituitary lymphoma complicating recurrent pituitary adenoma. A 56-year-old male with a history of pituitary adenoma was diagnosed with diffuse large B-cell lymphoma (DLBCL) of the left ocular adnexa, which was successfully treated by standard chemotherapy and local radiotherapy. Eight months later, he complained of diplopia and bitemporal hemianopia. Brain magnetic resonance imaging detected a suprasellar tumor. Transsphenoidal biopsy of the mass was performed, and histopathological examination revealed DLBCL admixed with pituitary adenoma. On a review of the literature, we found that pituitary lymphoma developing within adenoma is a recurrent phenomenon. The composite tumor is likely to be characterized by suprasellar involvement and presentation of visual disturbances. Moreover, in the present case, the suprasellar tumor remained visible after autologous peripheral stem cell transplant, likely due to the residual pituitary adenoma. We therefore recommend that refractory pituitary lymphoma should be vigorously biopsied in search of possibly underlying adenoma.

    View details for DOI 10.1007/s12185-012-1075-0

    View details for PubMedID 22527852